9.28
price down icon0.39%   -0.05
 
loading
Precedente Chiudi:
$9.33
Aprire:
$9.43
Volume 24 ore:
76,664
Relative Volume:
0.12
Capitalizzazione di mercato:
$561.50M
Reddito:
-
Utile/perdita netta:
$-106.81M
Rapporto P/E:
-4.2182
EPS:
-2.2
Flusso di cassa netto:
$-8.40M
1 W Prestazione:
-16.57%
1M Prestazione:
-21.96%
6M Prestazione:
-31.91%
1 anno Prestazione:
+16.91%
Intervallo 1D:
Value
$9.05
$9.7123
Intervallo di 1 settimana:
Value
$8.97
$11.19
Portata 52W:
Value
$6.93
$30.96

Immunome Inc Stock (IMNM) Company Profile

Name
Nome
Immunome Inc
Name
Telefono
610-321-3700
Name
Indirizzo
18702 N. CREEK PARKWAY, BOTHELL
Name
Dipendente
105
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
IMNM's Discussions on Twitter

Confronta IMNM con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
IMNM 9.27 561.50M 0 -106.81M -8.40M -2.20
VRTX 446.29 115.74B 10.63B -479.80M -1.35B 13.33
REGN 739.75 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 589.43 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 249.44 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 103.84 24.49B 3.30B -501.07M 1.03B 11.54

Immunome Inc Stock (IMNM) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-05-31 Iniziato Piper Sandler Overweight
2024-04-30 Iniziato JP Morgan Overweight
2024-04-15 Iniziato Guggenheim Buy
2024-01-29 Iniziato Leerink Partners Outperform
2023-12-19 Iniziato Wedbush Outperform
2021-10-29 Iniziato Cantor Fitzgerald Overweight
Mostra tutto

Immunome Inc Borsa (IMNM) Ultime notizie

pulisher
03:55 AM

Victory Capital Management Inc. Boosts Holdings in Immunome, Inc. (NASDAQ:IMNM) - Defense World

03:55 AM
pulisher
Nov 18, 2024

Wedbush Has Bullish Outlook for Immunome FY2024 Earnings - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

Leerink Partnrs Decreases Earnings Estimates for Immunome - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

FY2024 EPS Estimates for Immunome Lowered by Leerink Partnrs - Defense World

Nov 18, 2024
pulisher
Nov 16, 2024

Immunome Inc. Announces Third Quarter 2024 Financial Results and Pipeline Progress - Defense World

Nov 16, 2024
pulisher
Nov 15, 2024

Immunome Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Nov 15, 2024
pulisher
Nov 15, 2024

Immunome (NASDAQ:IMNM) Stock Price Down 7% After Analyst Downgrade - Defense World

Nov 15, 2024
pulisher
Nov 14, 2024

T. Rowe Price Investment Management, Inc. Expands Stake in Immun - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Piper Sandler maintains overweight on IMNM with $21 target By Investing.com - Investing.com Canada

Nov 14, 2024
pulisher
Nov 14, 2024

Piper Sandler maintains overweight on IMNM with $21 target - Investing.com India

Nov 14, 2024
pulisher
Nov 14, 2024

Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update - BioSpace

Nov 14, 2024
pulisher
Nov 14, 2024

Janus Henderson Group's Strategic Acquisition of Immunome Inc Sh - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Immunome (NASDAQ:IMNM) Shares Down 7% Following Analyst Downgrade - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Piper Sandler Cuts Immunome (NASDAQ:IMNM) Price Target to $21.00 - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Immunome price target lowered to $21 from $23 at Piper Sandler - TipRanks

Nov 14, 2024
pulisher
Nov 13, 2024

Immunome, Inc. Reports Q3 2024 Financial Results - TipRanks

Nov 13, 2024
pulisher
Nov 13, 2024

Immunome Inc (IMNM) Q3 2024 Earnings: Revenue Surpasses Estimates at $2.91M, GAAP EPS Misses at -$0.78 - GuruFocus.com

Nov 13, 2024
pulisher
Nov 13, 2024

Immunome, Inc. (IMNM) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance

Nov 13, 2024
pulisher
Nov 13, 2024

Immunome, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 13, 2024
pulisher
Nov 13, 2024

Immunome Reports $47.1M Q3 Loss, Advances Cancer Pipeline with Strong Cash Position | IMNM Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 13, 2024

(IMNM) Technical Pivots with Risk Controls - Stock Traders Daily

Nov 13, 2024
pulisher
Nov 13, 2024

Immunome earnings missed by $0.24, revenue topped estimates - Investing.com Canada

Nov 13, 2024
pulisher
Nov 13, 2024

FMR LLC's Strategic Acquisition of Immunome Inc Shares - GuruFocus.com

Nov 13, 2024
pulisher
Nov 10, 2024

Immunome (NASDAQ:IMNM) Shares Gap Up – Still a Buy? - Defense World

Nov 10, 2024
pulisher
Nov 09, 2024

Stephens & Co. Initiates Coverage of Immunome (IMNM) with Overweight Recommendation - MSN

Nov 09, 2024
pulisher
Nov 08, 2024

Analyst Expectations For Immunome's Future - Benzinga

Nov 08, 2024
pulisher
Nov 08, 2024

Immunome (NASDAQ:IMNM) Shares Gap UpTime to Buy? - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Immunome (NASDAQ:IMNM) Now Covered by Stephens - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Immunome, Inc. (NASDAQ:IMNM) Stake Reduced by Wealth Enhancement Advisory Services LLC - Defense World

Nov 08, 2024
pulisher
Nov 05, 2024

Immunome to Present at Guggenheim’s Inaugural Healthcare Innovation Conference - The Bakersfield Californian

Nov 05, 2024
pulisher
Nov 05, 2024

Vanguard Group Inc's Strategic Acquisition of Immunome Inc Shares - GuruFocus.com

Nov 05, 2024
pulisher
Nov 04, 2024

Immunome (NASDAQ:IMNM) Trading Up 8.7%Time to Buy? - MarketBeat

Nov 04, 2024
pulisher
Nov 02, 2024

Learn to Evaluate (IMNM) using the Charts - Stock Traders Daily

Nov 02, 2024
pulisher
Nov 01, 2024

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Nov 01, 2024
pulisher
Nov 01, 2024

Immunome, Inc. (NASDAQ:IMNM) Receives $29.00 Average PT from Brokerages - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Immunome, Inc. (NASDAQ:IMNM) Given Consensus Rating of “Buy” by Analysts - Defense World

Nov 01, 2024
pulisher
Oct 31, 2024

Immunome (NASDAQ: IMNM) Acquires Zentalis Pharmaceuticals’ Licensed Assets IMMUNOME, Inc. made a recent significant move on October 25, 2024, by acquiring Zentalis Pharmaceuticals, Inc.’s Licensed Assets. This acquisition was carried out thr - Defense World

Oct 31, 2024
pulisher
Oct 30, 2024

Immunome Advances with Strategic Asset Acquisition and Agreement - Yahoo Finance

Oct 30, 2024
pulisher
Oct 29, 2024

Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021 - Business Wire

Oct 29, 2024
pulisher
Oct 29, 2024

Immunome, Inc. (NASDAQ:IMNM) Short Interest Down 15.2% in October - MarketBeat

Oct 29, 2024
pulisher
Oct 25, 2024

Immunome's (IMNM) Outperform Rating Reiterated at Wedbush - MarketBeat

Oct 25, 2024
pulisher
Oct 18, 2024

Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium - The Bakersfield Californian

Oct 18, 2024
pulisher
Oct 18, 2024

IMNMImmunome, Inc. Latest Stock News & Market Updates - StockTitan

Oct 18, 2024
pulisher
Oct 15, 2024

Immunome (IMNM) Price Target Increased by 179.17% to 34.17 - MSN

Oct 15, 2024
pulisher
Oct 15, 2024

Cubist Systematic Strategies LLC Reduces Stake in Immunome, Inc. (NASDAQ:IMNM) - Defense World

Oct 15, 2024
pulisher
Oct 15, 2024

Cubist Systematic Strategies LLC Decreases Position in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat

Oct 15, 2024
pulisher
Oct 14, 2024

Understanding the Risks of Investing in Immunome Inc (IMNM) - Knox Daily

Oct 14, 2024
pulisher
Oct 14, 2024

Financial Metrics Exploration: Understanding Immunome Inc (IMNM) Through Ratios - The Dwinnex

Oct 14, 2024
pulisher
Oct 12, 2024

Sei Investments Co. Cuts Position in Immunome, Inc. (NASDAQ:IMNM) - Defense World

Oct 12, 2024
pulisher
Oct 11, 2024

(IMNM) Investment Analysis and Advice - Stock Traders Daily

Oct 11, 2024
pulisher
Oct 10, 2024

Insider Selling: Rosett Max, Immunome Inc [IMNM] Chief Financial Officer divested 14,380 shares - Knox Daily

Oct 10, 2024

Immunome Inc Azioni (IMNM) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Immunome Inc Azioni (IMNM) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Rosett Max
Chief Financial Officer
Sep 19 '24
Sale
16.01
14,380
230,224
47,476
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Capitalizzazione:     |  Volume (24 ore):